Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

The S&P 500 index is up 20% year to date with several high-profile companies ... The ability of the company to execute its ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

The company said that ... daily formulation has the potential to have a competitive profile in the oral GLP-1 space,” he said. Pfizer revealed in December that it had decided to drop the ...

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as ... and a series of high-profile failures of drugs in development, such ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

High-profile drug breakthroughs get a lot of attention ... A case in point: In November 2020, when Pfizer (PFE) and Moderna ...

Joining me on today's call are Ying Huang, the company's Chief Executive Officer ... We've call that CARVYKTI has a unique ...